Skip to main content

Breast Cancer Research and Treatment

Ausgabe 2/2019

Inhalt (26 Artikel)

Open Access Review

Second International Consensus Conference on lesions of uncertain malignant potential in the breast (B3 lesions)

Christoph J. Rageth, Elizabeth A. M. O’Flynn, Katja Pinker, Rahel A. Kubik-Huch, Alexander Mundinger, Thomas Decker, Christoph Tausch, Florian Dammann, Pascal A. Baltzer, Eva Maria Fallenberg, Maria P. Foschini, Sophie Dellas, Michael Knauer, Caroline Malhaire, Martin Sonnenschein, Andreas Boos, Elisabeth Morris, Zsuzsanna Varga

Review

Identifying adherence barriers to oral endocrine therapy among breast cancer survivors

Rutugandha Paranjpe, Grace John, Meghana Trivedi, Susan Abughosh

Review

Clinical findings and outcomes of MRI staging of breast cancer in a diverse population

Akshara Raghavendra, Julie Wecsler, Lingyun Ji, Pulin Sheth, Charite Ricker, Terry Church, Richard Sposto, Julie Lang, Stephen Sener, Linda Larsen, Debu Tripathy

Review

Peer support interventions for breast cancer patients: a systematic review

Jieman Hu, Xue Wang, Shaoning Guo, Fangfang Chen, Yuan-yu Wu, Fu-jian Ji, Xuedong Fang

Review

An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer

Anagha Gogate, Jason S. Rotter, Justin G. Trogdon, Ke Meng, Christopher D. Baggett, Katherine E. Reeder-Hayes, Stephanie B. Wheeler

Preclinical study

Genomic profile of breast sarcomas: a comparison with malignant phyllodes tumours

Sue Zann Lim, Cedric Chuan Young Ng, Vikneswari Rajasegaran, Peiyong Guan, Sathiyamoorthy Selvarajan, Aye Aye Thike, Nur Diyana Binte Md Nasir, Valerie Cui Yun Koh, Benita Kiat Tee Tan, Kong Wee Ong, Bin Tean Teh, Puay Hoon Tan

Preclinical study

KRT19 and CEACAM5 mRNA-marked circulated tumor cells indicate unfavorable prognosis of breast cancer patients

Xi-Mei Wang, Zhen Zhang, Li-Hui Pan, Xu-Chen Cao, Chunhua Xiao

Preclinical study

Overexpression of the cancer stem cell marker CD133 confers a poor prognosis in invasive breast cancer

Chitra Joseph, Maariya Arshad, Sasagu Kurozomi, Maryam Althobiti, Islam M. Miligy, Sara Al-izzi, Michael S. Toss, Fang Qin Goh, Simon J. Johnston, Stewart G. Martin, Ian O. Ellis, Nigel P. Mongan, Andrew R. Green, Emad A. Rakha

Preclinical study

The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies

Berry Button, Sarah Croessmann, David Chu, D. Marc Rosen, Daniel J. Zabransky, W. Brian Dalton, Karen Cravero, Kelly Kyker-Snowman, Ian Waters, Swathi Karthikeyan, Eric S. Christenson, Josh Donaldson, Tasha Hunter, Lauren Dennison, Cody Ramin, Betty May, Richard Roden, Dana Petry, Deborah K. Armstrong, Kala Visvanathan, Ben Ho Park

Open Access Preclinical study

Adipose stem cell crosstalk with chemo-residual breast cancer cells: implications for tumor recurrence

Matthew A. Lyes, Sturgis Payne, Paul Ferrell, Salvatore V. Pizzo, Scott T. Hollenbeck, Robin E. Bachelder

Clinical trial

Combination of different types of elastography in downgrading ultrasound Breast Imaging-Reporting and Data System category 4a breast lesions

Xueyi Zheng, Yini Huang, Yun Wang, Yubo Liu, Fei Li, Jing Han, Jianwei Wang, Longhui Cao, Jianhua Zhou

Clinical trial

Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

O. Nanni, D. Amadori, A. De Censi, A. Rocca, A. Freschi, A. Bologna, L. Gianni, F. Rosetti, L. Amaducci, L. Cavanna, F. Foca, S. Sarti, P. Serra, L. Valmorri, P. Bruzzi, D. Corradengo, A. Gennari, Laura Scaltriti, Gianni Michele Turolla, Claudio Dazzi, Laura Cortesi, Petros Giovanis, Silvana Saracchini, Mariangela Ciccarese, Francesco Carrozza

Clinical trial

Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer

Dilan A. Patel, Jing Xi, Jingqin Luo, Bilal Hassan, Shana Thomas, Cynthia X. Ma, Jian L. Campian

Clinical trial

Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer

Marius Wunderle, Jutta Pretscher, Sara Y. Brucker, Bernhard Volz, Arndt Hartmann, Cornelia Fiessler, Alexander Hein, Lothar Häberle, Sebastian M. Jud, Michael P. Lux, Wolfgang Janni, Christian R. Loehberg, Andreas D. Hartkopf, Christina B. Walter, Gerold Baake, Alexander Fridman, Wolfram Malter, Rachel Wuerstlein, Nadia Harbeck, Oliver Hoffmann, Sherko Kümmel, Bernhard Martin, Christoph Thomssen, Heiko Graf, Christopher Wolf, Christian M. Bayer, Carolin C. Hack, Katrin Almstedt, Paul Gass, Felix Heindl, Tobias F. Brodkorb, Naiba Nabieva, Christoph Lindner, Hans-Christian Kolberg, Petra Krabisch, Michael Weigel, Dieter Steinfeld-Birg, Andreas Kohls, Cosima Brucker, Volker Schulz, Gunnar Fischer, Volker Pelzer, Diethelm Wallwiener, Brigitte Rack, Tanja Fehm, Achim Rody, Nicolai Maass, Matthias W. Beckmann, Peter A. Fasching, Claudia Rauh

Epidemiology

A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families

Talia Donenberg, Sophia George, Jameel Ali, Gabriela Bravo, Karen Hernandez, Navin Sookar, Kimlin Tam Ashing, Steven A. Narod, Mohammad R. Akbari, Judith Hurley

Open Access Epidemiology

Significant inter- and intra-laboratory variation in grading of ductal carcinoma in situ of the breast: a nationwide study of 4901 patients in the Netherlands

Carmen van Dooijeweert, Paul J. van Diest, Stefan M. Willems, Chantal C. H. J. Kuijpers, Lucy I. H. Overbeek, Ivette A. G. Deckers

Epidemiology

Prevalence of breast cancer-related risk factors in underweight premenopausal women: the Korea National Health and Nutrition Examination Survey IV–VI

Joo Heung Kim, Kwang Hyun Yoon, Ho Hur, Seho Park, Jee Ye Kim, Hyung Seok Park, Seung II Kim, Young Up Cho, Byeong-Woo Park

Epidemiology

Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer

Emmanuel Caruana, Yohann Foucher, Philippe Tessier, Jean-Sébastien Frenel, Jean-Marc Classe, Etienne Dantan

Brief Report

Alternative transcript imbalance underlying breast cancer susceptibility in a family carrying PALB2 c.3201+5G>T

Laura Duran-Lozano, Gemma Montalban, Sandra Bonache, Alejandro Moles-Fernández, Anna Tenés, Marta Castroviejo-Bermejo, Estela Carrasco, Adrià López-Fernández, Sara Torres-Esquius, Neus Gadea, Neda Stjepanovic, Judith Balmaña, Sara Gutiérrez-Enríquez, Orland Diez

Letter to the Editor

Ectopic breast tissue and cancer

Alessandro Sindoni, Maria Gioffré-Florio, Fausto Famá

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.